{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:44:41Z","timestamp":1793295881361,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s13311-022-01183-1","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T11:05:15Z","timestamp":1642158315000},"page":"248-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":217,"title":["An Update on Psychopharmacological Treatment of Autism Spectrum Disorder"],"prefix":"10.1016","volume":"19","author":[{"given":"Ramkumar","family":"Aishworiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Valica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5029-8448","authenticated-orcid":false,"given":"Randi","family":"Hagerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibiana","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-022-01183-1_bib1","doi-asserted-by":"crossref","unstructured":"Maenner MJ, Shaw KA, Bakian AV, Bilder DA, Durkin MS, Esler A, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years \u2014 autism and developmental disabilities monitoring network, 11 sites, United States, 2018. Morbidity and mortality weekly report Surveillance summaries (Washington, DC : 2002). 2021;70(11):1\u201316.","DOI":"10.15585\/mmwr.ss7011a1"},{"key":"10.1007\/s13311-022-01183-1_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders-IV TR","author":"Johnson","year":"2000"},{"key":"10.1007\/s13311-022-01183-1_bib3","doi-asserted-by":"crossref","unstructured":"Hyman SL, Levy SE, Myers SM. Identification, evaluation, and management of children with autism spectrum disorder. Pediatrics. 2020;145(1).","DOI":"10.1542\/9781610024716-part01-ch002"},{"key":"10.1007\/s13311-022-01183-1_bib4","unstructured":"Association D-AP. Diagnostic and statistical manual of mental disorders. Arlington: American Psychiatric Publishing. 2013."},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib5","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1542\/peds.2013-0819","article-title":"Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis","volume":"133","author":"Doshi-Velez","year":"2014","journal-title":"Pediatrics"},{"issue":"7","key":"10.1007\/s13311-022-01183-1_bib6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10803-006-0123-0","article-title":"Comorbid psychiatric disorders in children with autism: interview development and rates of disorders","volume":"36","author":"Leyfer","year":"2006","journal-title":"J Autism Dev Disord"},{"issue":"12","key":"10.1007\/s13311-022-01183-1_bib7","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.rasd.2013.09.006","article-title":"Comorbidity in autism spectrum disorder: a literature review","volume":"7","author":"Mannion","year":"2013","journal-title":"Research in Autism Spectrum Disorders"},{"issue":"8","key":"10.1007\/s13311-022-01183-1_bib8","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/CHI.0b013e318179964f","article-title":"Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample","volume":"47","author":"Simonoff","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1037\/0022-006X.55.1.3","article-title":"Behavioral treatment and normal educational and intellectual functioning in young autistic children","volume":"55","author":"Lovaas","year":"1987","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40614-014-0005-2","article-title":"The evidence-based practice of applied behavior analysis","volume":"37","author":"Slocum","year":"2014","journal-title":"The Behavior Analyst"},{"key":"10.1007\/s13311-022-01183-1_bib11","doi-asserted-by":"crossref","unstructured":"Leaf JB, Leaf R, McEachin J, Taubman M, Ala'i-Rosales S, Ross RK, et al. Applied behavior analysis is a science and, therefore, progressive. Journal of autism and developmental disorders. 2016;46(2):720\u201331.","DOI":"10.1007\/s10803-015-2591-6"},{"issue":"3","key":"10.1007\/s13311-022-01183-1_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/104012370902100304","article-title":"Applied behavior analytic interventions for children with autism: a description and review of treatment research","volume":"21","author":"Granpeesheh","year":"2009","journal-title":"Ann Clin Psychiatry"},{"issue":"4","key":"10.1007\/s13311-022-01183-1_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10803-009-0825-1","article-title":"Evaluation of comprehensive treatment models for individuals with autism spectrum disorders","volume":"40","author":"Odom","year":"2010","journal-title":"J Autism Dev Disord"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF03392290","article-title":"What is evidence-based behavior analysis?","volume":"36","author":"Smith","year":"2013","journal-title":"The Behavior Analyst"},{"issue":"7","key":"10.1007\/s13311-022-01183-1_bib15","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s10803-014-2351-z","article-title":"Evidence-based practices for children, youth, and young adults with autism spectrum disorder: a comprehensive review","volume":"45","author":"Wong","year":"2015","journal-title":"J Autism Dev Disord"},{"key":"10.1007\/s13311-022-01183-1_bib16","doi-asserted-by":"crossref","unstructured":"Reichow B, Barton EE, Boyd BA, Hume K. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). The Cochrane database of systematic reviews. 2012;10:Cd009260.","DOI":"10.1002\/14651858.CD009260.pub2"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib17","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1542\/peds.2009-0958","article-title":"Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model","volume":"125","author":"Dawson","year":"2010","journal-title":"Pediatrics"},{"issue":"4","key":"10.1007\/s13311-022-01183-1_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/1362361303007004008","article-title":"Climbing the symbolic ladder in the DIR model through floor time\/interactive play","volume":"7","author":"Wieder","year":"2003","journal-title":"Autism"},{"key":"10.1007\/s13311-022-01183-1_bib19","unstructured":"Koegel RL, Koegel LK. Pivotal response treatments for autism: communication, social, & academic development: Paul H Brookes Publishing; 2006."},{"issue":"5","key":"10.1007\/s13311-022-01183-1_bib20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s10803-009-0901-6","article-title":"The TEACCH program in the era of evidence-based practice","volume":"40","author":"Mesibov","year":"2010","journal-title":"J Autism Dev Disord"},{"key":"10.1007\/s13311-022-01183-1_bib21","doi-asserted-by":"crossref","unstructured":"Hume K, Steinbrenner JR, Odom SL, Morin KL, Nowell SW, Tomaszewski B, et al. Evidence-based practices for children, youth, and young adults with autism: third generation review. Journal of Autism and Developmental Disorders. 2021:1\u201320.","DOI":"10.1007\/s10803-022-05438-w"},{"key":"10.1007\/s13311-022-01183-1_bib22","first-page":"2007","article-title":"Peer mediated instruction and intervention","volume":"8","author":"Hall","year":"2003","journal-title":"Wakefield, MA: National Center on Accessing the General Curriculum Retrieved February"},{"issue":"3","key":"10.1007\/s13311-022-01183-1_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/108835769400900301","article-title":"The picture exchange communication system","volume":"9","author":"Bondy","year":"1994","journal-title":"Focus on autistic behavior"},{"issue":"Supplement 1","key":"10.1007\/s13311-022-01183-1_bib24","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1542\/peds.2014-3667E","article-title":"Early intervention for children with autism spectrum disorder under 3 years of age: recommendations for practice and research","volume":"136","author":"Zwaigenbaum","year":"2015","journal-title":"Pediatrics"},{"issue":"9","key":"10.1007\/s13311-022-01183-1_bib25","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamapediatrics.2021.1329","article-title":"Medication use in the management of comorbidities among individuals with autism spectrum disorder from a large nationwide insurance database","volume":"175","author":"Feroe","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"4","key":"10.1007\/s13311-022-01183-1_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/DBP.0b013e3181d5d03b","article-title":"Autism spectrum disorder and co-occurring developmental, psychiatric, and medical conditions among children in multiple populations of the United States","volume":"31","author":"Levy","year":"2010","journal-title":"Journal of developmental and behavioral pediatrics : JDBP"},{"issue":"3","key":"10.1007\/s13311-022-01183-1_bib27","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1542\/peds.2007-0984","article-title":"Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders","volume":"121","author":"Mandell","year":"2008","journal-title":"Pediatrics"},{"issue":"Supplement 2","key":"10.1007\/s13311-022-01183-1_bib28","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1542\/peds.2012-0900D","article-title":"Use of psychotropic medication in children and adolescents with autism spectrum disorders","volume":"130","author":"Coury","year":"2012","journal-title":"Pediatrics"},{"issue":"5","key":"10.1007\/s13311-022-01183-1_bib29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1542\/peds.2012-3774","article-title":"Psychotropic medication use and polypharmacy in children with autism spectrum disorders","volume":"132","author":"Spencer","year":"2013","journal-title":"Pediatrics"},{"issue":"3","key":"10.1007\/s13311-022-01183-1_bib30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s10803-009-0878-1","article-title":"Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007\u20132008","volume":"40","author":"Rosenberg","year":"2010","journal-title":"J Autism Dev Disord"},{"issue":"2\u20133","key":"10.1007\/s13311-022-01183-1_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijdevneu.2004.08.002","article-title":"Significance of abnormalities in developmental trajectory and asymmetry of cortical serotonin synthesis in autism","volume":"23","author":"Chandana","year":"2005","journal-title":"Int J Dev Neurosci"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2040-2392-4-16","article-title":"Decreased tryptophan metabolism in patients with autism spectrum disorders","volume":"4","author":"Boccuto","year":"2013","journal-title":"Molecular autism"},{"key":"10.1007\/s13311-022-01183-1_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neuroscience.2012.08.038","article-title":"Brain-derived neurotrophic factor increases the motility of a particular N-methyl-D-aspartate\/GABA-responsive subset of neural progenitor cells","volume":"224","author":"Jansson","year":"2012","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-022-01183-1_bib34","doi-asserted-by":"crossref","unstructured":"Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews. 2013(8).","DOI":"10.1002\/14651858.CD004677.pub3"},{"key":"10.1007\/s13311-022-01183-1_bib35","doi-asserted-by":"crossref","unstructured":"Indah Winarni T, Chonchaiya W, Adams E, Au J, Mu Y, Rivera SM, et al. Sertraline may improve language developmental trajectory in young children with fragile x syndrome: a retrospective chart review. Autism research and treatment. 2012;2012.","DOI":"10.1155\/2012\/104317"},{"issue":"8","key":"10.1007\/s13311-022-01183-1_bib36","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/DBP.0000000000000334","article-title":"A randomized, double-blind, placebo-controlled trial of low-dose sertraline in young children with fragile X syndrome","volume":"37","author":"Hess","year":"2016","journal-title":"Journal of developmental and behavioral pediatrics: JDBP"},{"issue":"6","key":"10.1007\/s13311-022-01183-1_bib37","first-page":"00465","article-title":"Low-dose sertraline improves receptive language in children with fragile X syndrome when eye tracking methodology is used to measure treatment outcome","volume":"7","author":"Yoo","year":"2017","journal-title":"J Psychol Clin Psychiatry"},{"key":"10.1007\/s13311-022-01183-1_bib38","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3389\/fpsyt.2019.00810","article-title":"A randomized controlled trial of sertraline in young children with autism spectrum disorder","volume":"10","author":"Potter","year":"2019","journal-title":"Front Psych"},{"key":"10.1007\/s13311-022-01183-1_bib39","unstructured":"Hagerman Ba. Pediatric and Neurological assessments In: Hollander HaF, editor. Textbook of autism spectrum disorders 2nd edition: Am Psychiatric Assoc Publishing Washington DC; 2022. p. 87 - 100."},{"issue":"5","key":"10.1007\/s13311-022-01183-1_bib40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1007\/s13311-022-01183-1_bib41","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"issue":"8","key":"10.1007\/s13311-022-01183-1_bib42","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s10803-015-2361-5","article-title":"Co-occurring psychiatric disorders in preschool and elementary school-aged children with autism spectrum disorder","volume":"45","author":"Salazar","year":"2015","journal-title":"J Autism Dev Disord"},{"key":"10.1007\/s13311-022-01183-1_bib43","doi-asserted-by":"crossref","unstructured":"Mansour R, Ward AR, Lane DM, Loveland KA, Aman MG, Jerger S, et al. ADHD severity as a predictor of cognitive task performance in children with autism spectrum disorder (ASD). Research in Developmental Disabilities. 2021;111:103882.","DOI":"10.1016\/j.ridd.2021.103882"},{"issue":"2","key":"10.1007\/s13311-022-01183-1_bib44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1087054708326261","article-title":"Attention deficit\/hyperactivity disorder in children and adolescents with autism spectrum disorder: symptom or syndrome?","volume":"13","author":"Sinzig","year":"2009","journal-title":"J Atten Disord"},{"issue":"3","key":"10.1007\/s13311-022-01183-1_bib45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10803-010-1049-0","article-title":"Brief report: Are ADHD traits dissociable from the autistic profile? Links between cognition and behaviour","volume":"41","author":"Ames","year":"2011","journal-title":"J Autism Dev Disord"},{"key":"10.1007\/s13311-022-01183-1_bib46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1590\/S0004-282X2010000100022","article-title":"Frequency of symptoms of attention deficit and hyperactivity disorder in autistic children","volume":"68","author":"Pond\u00e9","year":"2010","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1007\/s13311-022-01183-1_bib47","doi-asserted-by":"crossref","unstructured":"Rong Y, Yang C-J, Jin Y, Wang Y. Prevalence of attention-deficit\/hyperactivity disorder in individuals with autism spectrum disorder: a meta-analysis. Research in Autism Spectrum Disorders. 2021;83:101759.","DOI":"10.1016\/j.rasd.2021.101759"},{"issue":"5","key":"10.1007\/s13311-022-01183-1_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/DBP.0000000000000285","article-title":"Effects of methylphenidate on sleep functioning in children with attention-deficit\/hyperactivity disorder","volume":"37","author":"Becker","year":"2016","journal-title":"Journal of developmental and behavioral pediatrics: JDBP"},{"issue":"9","key":"10.1007\/s13311-022-01183-1_bib49","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"The Lancet Psychiatry"},{"key":"10.1007\/s13311-022-01183-1_bib50","doi-asserted-by":"crossref","unstructured":"Sturman N, Deckx L, van Driel ML. Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database of Systematic Reviews. 2017(11).","DOI":"10.1002\/14651858.CD011144.pub2"},{"issue":"4","key":"10.1007\/s13311-022-01183-1_bib51","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.biopsych.2006.09.028","article-title":"Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures","volume":"61","author":"Posey","year":"2007","journal-title":"Biol Psychiat"},{"issue":"5","key":"10.1007\/s13311-022-01183-1_bib52","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/cap.2006.16.589","article-title":"A prospective open trial of guanfacine in children with pervasive developmental disorders","volume":"16","author":"Scahill","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1007\/s13311-022-01183-1_bib53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/1044546041649084","article-title":"Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases","volume":"14","author":"Posey","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1007\/s13311-022-01183-1_bib54","first-page":"77","article-title":"A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism","volume":"53","author":"Fankhauser","year":"1992","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1007\/s13311-022-01183-1_bib55","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/00004583-199912000-00017","article-title":"A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder","volume":"38","author":"Connor","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1007\/s13311-022-01183-1_bib56","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaac.2013.11.009","article-title":"Alpha-2 agonists for attention-deficit\/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy","volume":"53","author":"Hirota","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1007\/s13311-022-01183-1_bib57","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/jcpp.13305","article-title":"Practitioner Review: Pharmacological treatment of attention-deficit\/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis","volume":"62","author":"Rodrigues","year":"2021","journal-title":"J Child Psychol Psychiatry"},{"key":"10.1007\/s13311-022-01183-1_bib58","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3389\/fpsyt.2019.00366","article-title":"Systematic review of sleep disturbances and circadian sleep desynchronization in autism spectrum disorder: toward an integrative model of a self-reinforcing loop","volume":"10","author":"Carmassi","year":"2019","journal-title":"Front Psych"},{"issue":"9","key":"10.1007\/s13311-022-01183-1_bib59","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1212\/WNL.0000000000009033","article-title":"Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"94","author":"Buckley","year":"2020","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01183-1_bib60","doi-asserted-by":"crossref","unstructured":"Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL. Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 2017;56(11):948\u201357. e4.","DOI":"10.1016\/j.jaac.2017.09.414"},{"issue":"5","key":"10.1007\/s13311-022-01183-1_bib61","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1034\/j.1601-183X.2003.00037.x","article-title":"Model of autism: increased ratio of excitation\/inhibition in key neural systems","volume":"2","author":"Rubenstein","year":"2003","journal-title":"Genes Brain Behav"},{"issue":"11","key":"10.1007\/s13311-022-01183-1_bib62","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.biopsych.2012.01.014","article-title":"A randomized controlled pilot trial of oral N-acetylcysteine in children with autism","volume":"71","author":"Hardan","year":"2012","journal-title":"Biol Psychiat"},{"key":"10.1007\/s13311-022-01183-1_bib63","doi-asserted-by":"crossref","unstructured":"Sestili P, Fimognari C. Cytotoxic and antitumor activity of sulforaphane: the role of reactive oxygen species. Biomed Res Int. 2015;2015:402386.","DOI":"10.1155\/2015\/402386"},{"key":"10.1007\/s13311-022-01183-1_bib64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jbior.2018.11.006","article-title":"Sulforaphane as anticancer agent: a double-edged sword? Tricky balance between effects on tumor cells and immune cells","volume":"71","author":"Liang","year":"2019","journal-title":"Adv Biol Regul"},{"issue":"4","key":"10.1007\/s13311-022-01183-1_bib65","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12272-020-01225-2","article-title":"Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems","volume":"43","author":"Kamal","year":"2020","journal-title":"Arch Pharm Res"},{"issue":"4","key":"10.1007\/s13311-022-01183-1_bib66","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1631\/jzus.B1900614","article-title":"Effects of sulforaphane on brain mitochondria: mechanistic view and future directions","volume":"21","author":"Jardim","year":"2020","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1007\/s13311-022-01183-1_bib67","doi-asserted-by":"crossref","unstructured":"Uddin MS, Al Mamun A, Jakaria M, Thangapandiyan S, Ahmad J, Rahman MA, et al. Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders. Science of the Total Environment. 2020;707:135624.","DOI":"10.1016\/j.scitotenv.2019.135624"},{"key":"10.1007\/s13311-022-01183-1_bib68","doi-asserted-by":"crossref","unstructured":"Singh K, W Zimmerman A. Sulforaphane treatment of young men with autism spectrum disorder. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). 2016;15(5):597\u2013601.","DOI":"10.2174\/1871527315666160413122525"},{"issue":"43","key":"10.1007\/s13311-022-01183-1_bib69","doi-asserted-by":"crossref","first-page":"15550","DOI":"10.1073\/pnas.1416940111","article-title":"Sulforaphane treatment of autism spectrum disorder (ASD)","volume":"111","author":"Singh","year":"2014","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib70","first-page":"1","article-title":"Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder","volume":"12","author":"Zimmerman","year":"2021","journal-title":"Molecular autism"},{"issue":"5","key":"10.1007\/s13311-022-01183-1_bib71","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10803-010-1078-8","article-title":"A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder","volume":"41","author":"Bent","year":"2011","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"10.1007\/s13311-022-01183-1_bib72","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0278-5846(93)90058-Z","article-title":"A preliminary trial of ascorbic acid as supplemental therapy for autism","volume":"17","author":"Dolske","year":"1993","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-022-01183-1_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsbmb.2018.10.017","article-title":"A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder","volume":"187","author":"Mazahery","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"10.1007\/s13311-022-01183-1_bib74","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.yfrne.2011.07.001","article-title":"Prosocial effects of oxytocin and clinical evidence for its therapeutic potential","volume":"32","author":"Striepens","year":"2011","journal-title":"Front Neuroendocrinol"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2040-2392-3-16","article-title":"Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial","volume":"3","author":"Anagnostou","year":"2012","journal-title":"Molecular autism"},{"issue":"3","key":"10.1007\/s13311-022-01183-1_bib76","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/pcn.12205","article-title":"Resequencing and association analysis of OXTR with autism spectrum disorder in a Japanese population","volume":"69","author":"Egawa","year":"2015","journal-title":"Psychiatry Clin Neurosci"},{"issue":"8","key":"10.1007\/s13311-022-01183-1_bib77","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41380-018-0097-2","article-title":"Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial","volume":"25","author":"Yamasue","year":"2020","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13229-020-0313-1","article-title":"Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up","volume":"11","author":"Bernaerts","year":"2020","journal-title":"Molecular autism"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-94407-x","article-title":"Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism","volume":"11","author":"Mayer","year":"2021","journal-title":"Sci Rep"},{"issue":"7","key":"10.1007\/s13311-022-01183-1_bib80","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.biopsych.2009.09.020","article-title":"Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders","volume":"67","author":"Guastella","year":"2010","journal-title":"Biol Psychiat"},{"issue":"9","key":"10.1007\/s13311-022-01183-1_bib81","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mp.2015.162","article-title":"The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial","volume":"21","author":"Yatawara","year":"2016","journal-title":"Mol Psychiatry"},{"issue":"30","key":"10.1007\/s13311-022-01183-1_bib82","doi-asserted-by":"crossref","first-page":"8119","DOI":"10.1073\/pnas.1705521114","article-title":"Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism","volume":"114","author":"Parker","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1007\/s13311-022-01183-1_bib83","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.brainres.2014.01.049","article-title":"Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth","volume":"1580","author":"Anagnostou","year":"2014","journal-title":"Brain Res"},{"issue":"3","key":"10.1007\/s13311-022-01183-1_bib84","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10803-013-1899-3","article-title":"Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial","volume":"44","author":"Dadds","year":"2014","journal-title":"J Autism Dev Disord"},{"issue":"4","key":"10.1007\/s13311-022-01183-1_bib85","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/jcpp.12305","article-title":"The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial","volume":"56","author":"Guastella","year":"2015","journal-title":"J Child Psychol Psychiatry"},{"issue":"16","key":"10.1007\/s13311-022-01183-1_bib86","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJMoa2103583","article-title":"Intranasal oxytocin in children and adolescents with autism spectrum disorder","volume":"385","author":"Sikich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01183-1_bib87","doi-asserted-by":"crossref","first-page":"35054","DOI":"10.1038\/srep35054","article-title":"Intranasal oxytocin enhances connectivity in the neural circuitry supporting social motivation and social perception in children with autism","volume":"6","author":"Gordon","year":"2016","journal-title":"Sci Rep"},{"issue":"52","key":"10.1007\/s13311-022-01183-1_bib88","doi-asserted-by":"crossref","first-page":"20953","DOI":"10.1073\/pnas.1312857110","article-title":"Oxytocin enhances brain function in children with autism","volume":"110","author":"Gordon","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1007\/s13311-022-01183-1_bib89","doi-asserted-by":"crossref","unstructured":"Yamasue H, Domes G. Oxytocin and autism spectrum disorders. Behavioral Pharmacology of Neuropeptides: Oxytocin. 2017:449\u201365.","DOI":"10.1007\/7854_2017_24"},{"key":"10.1007\/s13311-022-01183-1_bib90","doi-asserted-by":"crossref","unstructured":"Huang Y, Huang X, Ebstein RP, Yu R. Intranasal oxytocin in the treatment of autism spectrum disorders: a multilevel meta-analysis. Neuroscience & Biobehavioral Reviews. 2021.","DOI":"10.1016\/j.neubiorev.2020.12.028"},{"issue":"5","key":"10.1007\/s13311-022-01183-1_bib91","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3390\/nu13051552","article-title":"Probiotic and oxytocin combination therapy in patients with autism spectrum disorder: a randomized, double-blinded, placebo-controlled pilot trial","volume":"13","author":"Kong","year":"2021","journal-title":"Nutrients"},{"key":"10.1007\/s13311-022-01183-1_bib92","doi-asserted-by":"crossref","unstructured":"Spanos M, Chandrasekhar T, Kim S-J, Hamer RM, King BH, McDougle CJ, et al. Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B). Contemporary Clinical Trials. 2020;98:106103.","DOI":"10.1016\/j.cct.2020.106103"},{"issue":"12","key":"10.1007\/s13311-022-01183-1_bib93","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/j.1651-2227.2010.01933.x","article-title":"The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects","volume":"99","author":"Lemonnier","year":"2010","journal-title":"Acta Paediatr"},{"key":"10.1007\/s13311-022-01183-1_bib94","doi-asserted-by":"crossref","unstructured":"Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Translational psychiatry. 2012;2(12):e202-e.","DOI":"10.1038\/tp.2012.124"},{"key":"10.1007\/s13311-022-01183-1_bib95","doi-asserted-by":"crossref","unstructured":"Lemonnier E, Villeneuve N, Sonie S, Serret S, Rosier A, Roue M, et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Translational psychiatry. 2017;7(3):e1056-e.","DOI":"10.1038\/tp.2017.10"},{"issue":"5","key":"10.1007\/s13311-022-01183-1_bib96","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1111\/apa.15723","article-title":"Bumetanide for autism: open-label trial in six children","volume":"110","author":"Fernell","year":"2021","journal-title":"Acta Paediatr"},{"issue":"7","key":"10.1007\/s13311-022-01183-1_bib97","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jaac.2020.07.888","article-title":"Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial","volume":"60","author":"Sprengers","year":"2021","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1007\/s13311-022-01183-1_bib98","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/cap.2015.0045","article-title":"A pilot study on the combination of applied behavior analysis and bumetanide treatment for children with autism","volume":"25","author":"Du","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"10.1007\/s13311-022-01183-1_bib99","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1007\/s10803-020-04709-8","article-title":"Bumetanide oral liquid formulation for the treatment of children and adolescents with autism spectrum disorder: Design of two phase III studies (SIGN Trials)","volume":"51","author":"Crutel","year":"2021","journal-title":"J Autism Dev Disord"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-21958-x","article-title":"Bumetanide for autism: more eye contact, less amygdala activation","volume":"8","author":"Hadjikhani","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1007\/s13311-022-01183-1_bib101","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1362361313514141","article-title":"Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study","volume":"19","author":"Hadjikhani","year":"2015","journal-title":"Autism"},{"key":"10.1007\/s13311-022-01183-1_bib102","doi-asserted-by":"crossref","unstructured":"Ben-Ari Y, Lemonnier E. Using bumetanide to treat autism appears promising but further clinical trials are needed to confirm this approach. Wiley Online Library; 2021.","DOI":"10.1111\/apa.15747"},{"issue":"5","key":"10.1007\/s13311-022-01183-1_bib103","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/1060028018817304","article-title":"Bumetanide for autism spectrum disorder in children: a review of randomized controlled trials","volume":"53","author":"James","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"1\u20133","key":"10.1007\/s13311-022-01183-1_bib104","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2010.07.017","article-title":"Fragile X mental retardation protein levels are decreased in major psychiatric disorders","volume":"124","author":"Fatemi","year":"2010","journal-title":"Schizophr Res"},{"issue":"7\u20138","key":"10.1007\/s13311-022-01183-1_bib105","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.neuropharm.2010.11.011","article-title":"The role of fragile X mental retardation protein in major mental disorders","volume":"60","author":"Fatemi","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-022-01183-1_bib106","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev-med-081117-041238","article-title":"Metformin for treatment of fragile X syndrome and other neurological disorders","volume":"70","author":"Gantois","year":"2019","journal-title":"Annu Rev Med"},{"issue":"8","key":"10.1007\/s13311-022-01183-1_bib107","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/mp.2016.51","article-title":"Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model","volume":"22","author":"Monyak","year":"2017","journal-title":"Mol Psychiatry"},{"issue":"4","key":"10.1007\/s13311-022-01183-1_bib108","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3892\/mmr.2012.753","article-title":"Effect of metformin on the proliferation, migration, and MMP-2 and-9 expression of human umbilical vein endothelial cells","volume":"5","author":"Esfahanian","year":"2012","journal-title":"Mol Med Rep"},{"issue":"2","key":"10.1007\/s13311-022-01183-1_bib109","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/cge.13039","article-title":"Metformin as targeted treatment in fragile X syndrome","volume":"93","author":"Dy","year":"2018","journal-title":"Clin Genet"},{"key":"10.1007\/s13311-022-01183-1_bib110","doi-asserted-by":"crossref","unstructured":"Biag HMB, Potter LA, Wilkins V, Afzal S, Rosvall A, Salcedo\u2010Arellano MJ, et al. Metformin treatment in young children with fragile X syndrome. Molecular genetics & genomic medicine. 2019;7(11):e956.","DOI":"10.1002\/mgg3.956"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib111","first-page":"1","article-title":"Prepubertal metformin treatment in fragile X syndrome alleviated macroorchidism: a case study","volume":"3","author":"Protic","year":"2019","journal-title":"Advances in Clinical and Translational Research"},{"key":"10.1007\/s13311-022-01183-1_bib112","doi-asserted-by":"crossref","unstructured":"Protic D, Aydin EY, Tassone F, Tan MM, Hagerman RJ, Schneider A. Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin\u2010two cases. Molecular genetics & genomic medicine. 2019;7(7):e00745.","DOI":"10.1002\/mgg3.745"},{"issue":"2","key":"10.1007\/s13311-022-01183-1_bib113","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuron.2012.01.034","article-title":"Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome","volume":"77","author":"Osterweil","year":"2013","journal-title":"Neuron"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-020-09315-4","article-title":"Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome","volume":"12","author":"Thurman","year":"2020","journal-title":"J Neurodev Disord"},{"key":"10.1007\/s13311-022-01183-1_bib115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jcomdis.2018.02.007","article-title":"Inferential language use by school-aged boys with fragile X syndrome: effects of a parent-implemented spoken language intervention","volume":"72","author":"Nelson","year":"2018","journal-title":"J Commun Disord"},{"key":"10.1007\/s13311-022-01183-1_bib116","doi-asserted-by":"crossref","unstructured":"Patricio F, Morales-Andrade AA, Patricio-Mart\u00ednez A, Lim\u00f3n ID. Cannabidiol as a therapeutic target: Evidence of its neuroprotective and neuromodulatory function in parkinson's disease. Frontiers in Pharmacology. 2020;11.","DOI":"10.3389\/fphar.2020.595635"},{"key":"10.1007\/s13311-022-01183-1_bib117","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","article-title":"The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors","volume":"119","author":"Bakas","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1007\/s13311-022-01183-1_bib118","doi-asserted-by":"crossref","unstructured":"Leweke F, Piomelli D, Pahlisch F, Muhl D, Gerth C, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational psychiatry. 2012;2(3):e94-e.","DOI":"10.1038\/tp.2012.15"},{"issue":"8","key":"10.1007\/s13311-022-01183-1_bib119","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem Res"},{"issue":"10125","key":"10.1007\/s13311-022-01183-1_bib120","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"The Lancet"},{"key":"10.1007\/s13311-022-01183-1_bib121","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbr.2015.05.003","article-title":"Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome","volume":"291","author":"Qin","year":"2015","journal-title":"Behav Brain Res"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib122","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/can.2015.0008","article-title":"Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment","volume":"1","author":"Wei","year":"2016","journal-title":"Cannabis and cannabinoid research"},{"key":"10.1007\/s13311-022-01183-1_bib123","series-title":"Taylor and Hollander Cannabis, Cannabionids and Immunomodulary agents","first-page":"586","author":"Nezgovorva","year":"2022"},{"key":"10.1007\/s13311-022-01183-1_bib124","unstructured":"Heussler H, Michael Duhig TH, Carol O'Neill, Donna Gutterman, Joseph M. Palumbo, Terri Sebree. Longer term tolerability and efficacy of ZYN002 cannabidiol transdermal gel in children and adolescents with autism spectrum disorder (ASD): an open label phase 2 study (BRIGHT [ZYN2 CL 030]). Society for Developmental and Behavioral Pediatrics Annual Meeting USA2021."},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: a proof-of-concept randomized trial","volume":"12","author":"Aran","year":"2021","journal-title":"Molecular Autism"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-019-9277-x","article-title":"A phase 1\/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome","volume":"11","author":"Heussler","year":"2019","journal-title":"J Neurodev Disord"},{"issue":"9","key":"10.1007\/s13311-022-01183-1_bib127","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/npp.2015.66","article-title":"GABA B receptor agonist R-baclofen reverses social deficits and reduces repetitive behavior in Two mouse models of autism","volume":"40","author":"Silverman","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-022-01183-1_bib128","doi-asserted-by":"crossref","unstructured":"Stoppel LJ, Kazdoba TM, Schaffler MD, Preza AR, Heynen A, Crawley JN, et al. R-baclofen reverses cognitive deficits and improves social interactions in two lines of 16p11. 2 deletion mice. Neuropsychopharmacology. 2018;43(3):513\u201324.","DOI":"10.1038\/npp.2017.236"},{"key":"10.1007\/s13311-022-01183-1_bib129","doi-asserted-by":"crossref","unstructured":"Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Science translational medicine. 2012;4(152):152ra28-ra28.","DOI":"10.1126\/scitranslmed.3004218"},{"key":"10.1007\/s13311-022-01183-1_bib130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fncel.2015.00034","article-title":"Update on the implication of potassium channels in autism: K+ channelautism spectrum disorder","volume":"9","author":"Guglielmi","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"10.1007\/s13311-022-01183-1_bib131","doi-asserted-by":"crossref","unstructured":"Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Science translational medicine. 2012;4(152):152ra27-ra27.","DOI":"10.1126\/scitranslmed.3004214"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-016-9181-6","article-title":"Arbaclofen in fragile X syndrome: results of phase 3 trials","volume":"9","author":"Berry-Kravis","year":"2017","journal-title":"J Neurodev Disord"},{"issue":"6","key":"10.1007\/s13311-022-01183-1_bib133","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1073\/pnas.0812394106","article-title":"Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice","volume":"106","author":"Tropea","year":"2009","journal-title":"Proc Natl Acad Sci"},{"issue":"7475","key":"10.1007\/s13311-022-01183-1_bib134","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nature12618","article-title":"SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients","volume":"503","author":"Shcheglovitov","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13229-020-00359-w","article-title":"IGF-1 treatment causes unique transcriptional response in neurons from individuals with idiopathic autism","volume":"11","author":"Linker","year":"2020","journal-title":"Molecular Autism"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2040-2392-4-9","article-title":"Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay","volume":"4","author":"Bozdagi","year":"2013","journal-title":"Molecular autism"},{"issue":"16","key":"10.1007\/s13311-022-01183-1_bib137","doi-asserted-by":"crossref","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","article-title":"Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome","volume":"92","author":"Glaze","year":"2019","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01183-1_bib138","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pediatrneurol.2020.04.019","article-title":"A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of fragile X syndrome","volume":"110","author":"Berry-Kravis","year":"2020","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib139","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12017-015-8341-2","article-title":"NNZ-2566, a novel analog of (1\u20133) IGF-1, as a potential therapeutic agent for fragile X syndrome","volume":"17","author":"Deacon","year":"2015","journal-title":"NeuroMol Med"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.410310105","article-title":"Cyclic AMP metabolism in fragile X syndrome","volume":"31","author":"Berry-Kravis","year":"1992","journal-title":"Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society"},{"key":"10.1007\/s13311-022-01183-1_bib141","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fnbeh.2016.00136","article-title":"Multiple drug treatments that increase cAMP signaling restore long-term memory and aberrant signaling in fragile X syndrome models","volume":"10","author":"Choi","year":"2016","journal-title":"Front Behav Neurosci"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-15028-x","article-title":"Multiple behavior phenotypes of the fragile-X syndrome mouse model respond to chronic inhibition of phosphodiesterase-4D (PDE4D)","volume":"7","author":"Gurney","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1007\/s13311-022-01183-1_bib143","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41591-021-01321-w","article-title":"Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial","volume":"27","author":"Berry-Kravis","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1007\/s13311-022-01183-1_bib144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-94079-7","article-title":"Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy","volume":"11","author":"Reyes","year":"2021","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-022-01183-1_bib145","doi-asserted-by":"crossref","unstructured":"Kaufmann WE, Sprouse J, Rebowe N, Hanania T, Klamer D, Missling CU. ANAVEX\u00ae 2\u201373 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome. Pharmacology Biochemistry and Behavior. 2019;187:172796.","DOI":"10.1016\/j.pbb.2019.172796"},{"key":"10.1007\/s13311-022-01183-1_bib146","doi-asserted-by":"crossref","unstructured":"Hampel H, Williams C, Etcheto A, Goodsaid F, Parmentier F, Sallantin J, et al. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: analysis of the blarcamesine (ANAVEX2\u201073) Phase 2a clinical study. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2020;6(1):e12013.","DOI":"10.1002\/trc2.12013"},{"key":"10.1007\/s13311-022-01183-1_bib147","doi-asserted-by":"crossref","unstructured":"Macfarlane S, Maruff P, Cecchi M, Moore D, Zografidis T, Missling C. P1\u2013046: New exploratory Alzheimer'sdDrug Anavex 2\u201373: dose dependent clinical cognitive improvement observed in mini mental state examination (MMSE) and other cognitive markers in a phase 2A study in mild-to-moderate Alzheimer's patients. Alzheimer's & Dementia. 2016;12:P419-P.","DOI":"10.1016\/j.jalz.2016.06.793"},{"issue":"2","key":"10.1007\/s13311-022-01183-1_bib148","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tins.2019.12.002","article-title":"The sigma-1 receptor at the crossroad of proteostasis, neurodegeneration, and autophagy","volume":"43","author":"Christ","year":"2020","journal-title":"Trends Neurosci"},{"issue":"4","key":"10.1007\/s13311-022-01183-1_bib149","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/WCO.0000000000000954","article-title":"Fragile X-associated tremor\/ataxia syndrome: Pathophysiology and management","volume":"34","author":"Hagerman","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"10.1007\/s13311-022-01183-1_bib150","doi-asserted-by":"crossref","unstructured":"Frye RE, editor Mitochondrial dysfunction in autism spectrum disorder: Unique abnormalities and targeted treatments. Seminars in pediatric neurology; 2020: Elsevier.","DOI":"10.1016\/j.spen.2020.100829"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01183-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01183-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01183-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:33:50Z","timestamp":1761806030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923001654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":150,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1878747923001654"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01183-1","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Update on Psychopharmacological Treatment of Autism Spectrum Disorder","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01183-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}